Cerenome Reported $1.55 Million in Q3 Billing
The Houston company saw growth in its diagnostic testing business as it moves toward a new Medicare pricing decision.
Updated on Sept. 30, 2026 in Economic Indicators
Live Poll
Do you believe expanding diagnostic testing coverage improves patient access to necessary care?
Cerenome recorded $1.55 million in gross billings for its CNSide tests during the third quarter of 2026. This performance followed the submission of 222 tests, as the company prepares for a potential Medicare pricing adjustment.
Why it matters
The company’s ability to secure favorable pricing for its tests has direct implications for insurance coverage and out-of-pocket costs for households utilizing the diagnostic platform. Ongoing regulatory milestones are central to its efforts to expand access to its testing menu.
Cerenome reported $1.55 million in unaudited gross billings for 222 tests in Q3 2026. The firm currently serves 158 million contracted covered lives and projects reaching approximately 200 million lives by early 2027.
The players
Cerenome
A Houston-based diagnostic company that develops testing platforms for healthcare providers and patients.
CMS
The federal agency responsible for managing Medicare and Medicaid coverage and pricing policies for medical services.
The details
Gross billings reflect the list prices of tests submitted to insurance providers through September 30, 2026. Management is now targeting an annualized billing run rate of $10 million to $12 million for the fourth quarter. These figures provide a baseline for the company's financial health as it seeks to finalize Medicare pricing for code 0640U.
Timeline
Q3 2026: Cerenome billed 222 tests for $1.55 million.
Q4 2026: The company plans to launch new molecular profile and protein expression assays.
January 1, 2027: This is the target effective date for a CMS Medicare pricing decision.
Early 2027: Cerenome targets having 200 million covered lives and beneficiaries.
Money Landscape
The company's financial growth remains closely tied to the CMS Medicare pricing decision for its diagnostic code. This development follows a pattern of medical diagnostic firms working to align new testing platforms with national health insurance coverage standards.
Readers covered by Medicare or private insurance plans should watch for updates on coverage eligibility for diagnostic tests. Speak with your healthcare provider or a qualified billing professional to understand how new pricing codes may affect your out-of-pocket costs for medical procedures.
The takeaway
Financial performance for diagnostic providers is heavily influenced by upcoming federal pricing determinations. Patients should monitor future insurance statements for changes related to diagnostic billing codes to ensure accurate coverage and billing.
What happens next
A CMS Medicare pricing decision is targeted to take effect on January 1, 2027.
Further reading
For more background on how medical coverage shifts impact the local market, see Economic Indicators.
More information
For additional details on the company's services, visit the CNSide diagnostic platform information.
Live Poll
Do you believe expanding diagnostic testing coverage improves patient access to necessary care?
